Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma.
Methylated cyclin D2 gene circulating in the blood as a prognosis predictor of hepatocellular carcinoma.
复制标题
DOI:
10.1016/j.cca.2010.01.004
复制
发表时间:
2010-04
期刊:
影响因子:
--
通讯作者:
M. Tsutsui;N. Iizuka;T. Moribe;T. Miura;Naoki Kimura;S. Tamatsukuri;H. Ishitsuka;Y. Fujita;Y. H
中科院分区:
文献类型:
--
作者:
M. Tsutsui;N. Iizuka;T. Moribe;T. Miura;Naoki Kimura;S. Tamatsukuri;H. Ishitsuka;Y. Fujita;Y. H
BACKGROUNDPrognosis of hepatocellular carcinoma (HCC) remains poor because of high recurrence rate. We examined preoperatively the methylated CCND2 gene levels present in the serum following release from HCC cells as a prognosis predictor in patients undergoing curative hepatectomy.METHODSQuantitative real-time RT-PCR and quantitative methylation-specific PCR were used to measure methylated CCND2 gene and its mRNA levels.RESULTSThe CCND2 mRNA levels were down-regulated in HCC with early intrahepatic recurrence (IHR) within 1year of curative hepatectomy. We also identified that this down-regulation was due to promoter hypermethylation. In 70 HCC patients who underwent curative hepatectomy, 39 patients sero-positive for the methylated CCND2 gene (>70pg/ml serum) exhibited a significantly shorter disease-free survival (DFS) period (P=0.02) than the 31 patients who were sero-negative for the methylated CCND2 gene. None of the sero-negative patients demonstrated early IHR, and this method of serum testing did not produce any false-negative predictions for early IHR. Multivariate analysis showed that the serum level of methylated CCND2 was an independent risk factor for DFS (hazard ratio of 1.866, 95% CI: 1.106–3.149).CONCLUSIONMethylated CCND2 gene in the serum serves as a prognosis predictor of HCC after curative hepatectomy.